Danaher Corporation (DHR) is posed to gain from strength in the Life Sciences segment and accretive acquisitions.However, softness in the Biotechnology segment raises concerns for the company. Decreased demand in the bioprocessing business has been weighing on the performance of the segment. Given the company’s international exposure, forex woes are weighing on its top line.What’s Aiding DHR?Business Strength: Stable demand in the academic and applied markets and strong momentum in the genomics consumables ...